Inhibition of membrane Na+ channels by a type botulinum toxin at femtomolar concentrations in central and peripheral neurons

Journal of Pharmacological Sciences

Volumn 118, Issue 1, 2012, Pages 33-42

  Shin, Min Chul ^a   Wakita, Masahito ^a   Xie, Du Jie ^a,b   Yamaga, Toshitaka ^a,c   Iwata, Satomi ^a   Torii, Yasushi ^d   Harakawa, Tetsuhiro ^d   Ginnaga, Akihiro ^d   Kozaki, Shunji ^e   Akaike, Norio ^a  

^a KUMAMOTO HEALTH SCIENCE UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU INSTITUTE OF TECHNOLOGY   (Japan)

^d Chemo Sero Therapeutic Research Institute   (Japan)

^e Osaka Prefecture University   (Japan)

Author keywords

A2 type neurotoxin (A2NTX); Botulinum toxin; Dorsal root ganglion (DRG) neuron; Hippocampal CA1 neuron

Indexed keywords

BOTULINUM TOXIN A; FLUNARIZINE; LAMOTRIGINE; PHENYTOIN; PROCAINE; SODIUM CHANNEL; TETRODOTOXIN;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HIPPOCAMPAL CA1 REGION; NERVE CELL; NERVE FIBER MEMBRANE POTENTIAL; NONHUMAN; RAT; SODIUM CURRENT; SPINAL GANGLION;

EID: 84856575905     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.11060FP     Document Type: Article

References (48)

1. Johnson EA. Clostridium botulinum neurotoxins - applications in medicine and potential agents of bioterrorism. Clin Microbiol Newslett. 2005;27:147-151. (Pubitemid 41399871)
2. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000;80:717-766. (Pubitemid 30164948)
3. Antonucci F, Di GA, Novelli E, Manno I, Sartucci F, Bozzi Y, et al. Botulinum neurotoxin E (BoNT/E) reduces CA1 neuron loss and granule cell dispersion, with no effects on chronic seizures, in a mouse model of temporal lobe epilepsy. Exp Neurol. 2008;210:388-401.
4. Manno I, Antonucci F, Caleo M, Bozzi Y. BoNT/E prevents seizure- induced activation of caspase 3 in the rat hippocampus. Neuroreport. 2007;18:577-580. (Pubitemid 46594918)
5. Costantin L, Bozzi Y, Richichi C, Viegi A, Antonucci F, Funicello M, et al. Antiepileptic effects of botulinum neurotoxin E. J Neurosci. 2005;25:1943-1951. (Pubitemid 40289399)
6. Antonucci F, Bozzi Y, Caleo M. Intrahippocampal infusion of botulinum neurotoxin E (BoNT/E) reduces spontaneous recurrent seizures in a mouse model of mesial temporal lobe epilepsy. Epilepsia. 2009;50:963-966.
7. Rossetto O, Seveso M, Caccin P, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: turning bad guys into good by research. Toxicon. 2001;39:27-41. (Pubitemid 30628927)
8. Foran PG, Mohammed N, Lisk GO, Nagwaney S, Lawrence GW, Johnson E, et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem. 2003;278:1363-1371. (Pubitemid 36790822)
9. Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett. 1998;256:135-138. (Pubitemid 28546908)
10. Reynolds EH. The ILAE/IBE/WHO epilepsy global campaign history. International League Against Epilepsy. International Bureau for Epilepsy. Epilepsia. 2002;43 Suppl 6:9-11.
11. Aird RB. The importance of seizure-inducing factors in the control of refractory forms of epilepsy. Epilepsia. 1983;24:567-583. (Pubitemid 14225331)
12. Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res. 1999;34:109-122. (Pubitemid 29155481)
13. Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol. 2010;9:413-424.
14. Akaike N, Ito Y, Shin MC, Nonaka K, Torii Y, Harakawa T, et al. Effects of A2 type botulinum toxin on spontaneous miniature and evoked transmitter release from the rat spinal excitatory and inhibitory synapses. Toxicon. 2010;56:1315-1326.
15. Matteoli M, Pozzi D, Grumelli C, Condliffe SB, Frassoni C, Harkany T, et al. The synaptic split of SNAP-25: different roles in glutamatergic and GABAergic neurons? Neuroscience. 2009;158:223-230.
16. Bozzi Y, Costantin L, Antonucci F, Caleo M. Action of botulinum neurotoxins in the central nervous system: antiepileptic effects. Neurotox Res. 2006;9:197-203.
17. Akaike N, Murakami N, Katsurabayashi S, Jin YH, Imazawa T. Focal stimulation of single GABAergic presynaptic boutons on the rat hippocampal neuron. Neurosci Res. 2002;42:187-195. (Pubitemid 34230407)
18. Akaike N, Moorhouse AJ. Techniques: applications of the nervebouton preparation in neuropharmacology. Trends Pharmacol Sci. 2003;24:44-47. (Pubitemid 36009290)
19. Tokutomi N, Ozoe Y, Katayama N, Akaike N. Effects of lindane (gamma-BHC) and related convulsants on GABAA receptor-operated chloride channels in frog dorsal root ganglion neurons. Brain Res. 1994;643:66-73.
20. Shin MC, Kim CJ, Min BI, Ogawa S, Tanaka E, Akaike N. A selective T-type Ca2+ channel blocker R(-) efonidipine. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:411-421.
21. Akaike N. T-type calcium channel in mammalian CNS neurones. Comp Biochem Physiol C. 1991;98:31-40.
22. Uneyama C, Uneyama H, Takahashi M, Akaike N. Cytoplasmic pH regulates ATP-induced Ca(2+)-dependent K(+)-current oscillation in rat megakaryocytes. Biochem J. 1993;295(Pt 1): 317-320. (Pubitemid 23298344)
23. Takahashi K, Akaike N. Calcium antagonist effects on lowthreshold (T-type) calcium current in rat isolated hippocampal CA1 pyramidal neurons. J Pharmacol Exp Ther. 1991;256:169-175.
24. Kozaki S, Togashi S, Sakaguchi G. Separation of Clostridium botulinum type A derivative toxin into two fragments. Jpn J Med Sci Biol. 1981;34:61-68. (Pubitemid 11012237)
25. Akaike N, Harata N. Nystatin perforated patch recording and its applications to analyses of intracellular mechanisms. Jpn J Physiol. 1994;44:433-473.
26. Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol. 2010;9:413-424.
27. Elliott AA, Elliott JR. Characterization of TTX-sensitive and TTX-resistant sodium currents in small cells from adult rat dorsal root ganglia. J Physiol. 1993;463:39-56. (Pubitemid 23120575)
28. Ogata N, Tatebayashi H. Ontogenic development of the TTXsensitive and TTX-insensitive Na+ channels in neurons of the rat dorsal root ganglia. Brain Res Dev Brain Res. 1992;65:93-100.
29. Tedroff K, Tedroff J. In: Ward AB, Barnes MP, editors. Clinical uses of botulinum toxin. Cambridge: Cambridge University Press; 2007. p. 382.
30. Fozzard HA, Lipkind GM. The tetrodotoxin binding site is within the outer vestibule of the sodium channel. Mar Drugs. 2010;8:219-234.
31. Matak I, Bach-Rojecky L, Filipovic B, Lackovic Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience. 2011;186:201-207.
32. Kitamura Y, Matsuka Y, Spigelman I, Ishihara Y, Yamamoto Y, Sonoyama W, et al. Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience. 2009;159:1422-1429.
33. Fischer A, Montal M. Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc Natl Acad Sci U S A. 2007;104:10447-10452. (Pubitemid 47185685)
34. Donovan JJ, Middlebrook JL. Ion-conducting channels produced by botulinum toxin in planar lipid membranes. Biochemistry. 1986;25:2872-2876. (Pubitemid 16073823)
35. Hoch DH, Romero-Mira M, Ehrlich BE, Finkelstein A, DasGupta BR, Simpson LL. Channels formed by botulinum, tetanus, and diphtheria toxins in planar lipid bilayers: relevance to translocation of proteins across membranes. Proc Natl Acad Sci U S A. 1985;82:1692-1696. (Pubitemid 15079459)
36. Sheridan RE. Gating and permeability of ion channels produced by botulinum toxin types A and E in PC12 cell membranes. Toxicon. 1998;36:703-717. (Pubitemid 28280980)
37. Fischer A, Montal M. Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J Biol Chem. 2007;282:29604-29611. (Pubitemid 350043363)
38. Fernandez-Salas E, Ho H, Garay P, Steward LE, Aoki KR. Is the light chain subcellular localization an important factor in botulinum toxin duration of action? Mov Disord. 2004;19 Suppl 8: S23-S34. (Pubitemid 38967508)
39. de Paiva A, Dolly JO. Light chain of botulinum neurotoxin is active in mammalian motor nerve terminals when delivered via liposomes. FEBS Lett. 1990;277:171-174.
40. John VH, Main MJ, Powell AJ, Gladwell ZM, Hick C, Sidhu HS, et al. Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23. Neuropharmacology. 2004;46:425-438. (Pubitemid 38223876)
41. Rush AM, Elliott JR. Phenytoin and carbamazepine: differential inhibition of sodium currents in small cells from adult rat dorsal root ganglia. Neurosci Lett. 1997;226:95-98. (Pubitemid 27190414)
42. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics. 2007;4:18-61. (Pubitemid 46107329)
43. Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol. 2010;9:413-424.
44. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. BMJ. 1995;311:1047-1052.
45. Lang DG, Wang CM, Cooper BR. Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J Pharmacol Exp Ther. 1993;266:829-835. (Pubitemid 23318697)
46. Luvisetto S, Marinelli S, Lucchetti F, Marchi F, Cobianchi S, Rossetto O, et al. Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice. Brain Res. 2006;1082:124-131.
47. Naumann M, Yakovleff A, Durif F. A randomized, doublemasked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol. 2002;249:57-63. (Pubitemid 34119024)
48. Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 1990; 40:1213-1218. (Pubitemid 20244977)